食管癌的靶向治疗研究进展
发布时间：2019-05-17 08:52
【摘要】：正食管癌是指下咽到食管胃结合部之间食管上皮来源的癌,男性较多。在我国食管癌是一种常见的恶性肿瘤,目前占我国肿瘤死亡率的第4位。我国的食管癌90%以上为鳞状细胞癌,少数为腺癌。食管癌患者就诊时绝大多数已属于中晚期。目前食管癌的主要治疗手段仍然是手术、放射治疗和化疗。然而无论是手术还是放化疗其临床疗效均远不能令人满意,手术的5年生存率为15%~39%;而放化疗的5年生存率为8%~15%。分子靶向治疗是在细胞分子水平
[Abstract]:Positive esophageal cancer refers to the esophageal epithelial origin from hypopharynx to the junction of esophagus and stomach, which is more in men. Esophageal cancer is a common malignant tumor in China, which accounts for the fourth place of tumor mortality in China. More than 90% of esophageal cancer in China is squamous cell carcinoma and a few are adenocarcinoma. Most of the patients with esophageal cancer were in the middle and late stages. At present, the main treatment of esophageal cancer is still surgery, radiotherapy and chemotherapy. However, the clinical efficacy of both surgery and radiotherapy and chemotherapy was far from satisfactory. The 5-year survival rate was 15% 鈮，
本文编号：2478964
[Abstract]:Positive esophageal cancer refers to the esophageal epithelial origin from hypopharynx to the junction of esophagus and stomach, which is more in men. Esophageal cancer is a common malignant tumor in China, which accounts for the fourth place of tumor mortality in China. More than 90% of esophageal cancer in China is squamous cell carcinoma and a few are adenocarcinoma. Most of the patients with esophageal cancer were in the middle and late stages. At present, the main treatment of esophageal cancer is still surgery, radiotherapy and chemotherapy. However, the clinical efficacy of both surgery and radiotherapy and chemotherapy was far from satisfactory. The 5-year survival rate was 15% 鈮，
本文编号：2478964
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2478964.html
